Dr. Lucas Przymusinski is an internal medicine physician and partner in DLA Piper's Product Liability, Mass Tort and Product Stewardship group.  He focuses his practice on drug and device litigation, mass torts, product liability, and regulatory issues.  For the past two years, Dr. Przymusinski has been recognized by Legal 500 as a Next Generation Partner in the Healthcare & Life Sciences sector.

Dr. Przymusinski has led the scientific and legal defense of numerous mass tort litigations, representing some of the largest pharmaceutical and medical device manufacturers.  He has been involved in every stage of litigation, including strategic assessment and planning, motion practice, expert development, trial and appellate practice.

Dr. Przymusinski also regularly counsels life sciences clients on litigation, regulatory, risk management and mitigation, corporate governance and other product-related issues.  He also helps guide clients through the FDA Advisory Committee process and assists in developing strategic responses to product safety-issues, recalls and related FDA enforcement actions.